PA
RHLD

PharVision Advisers’s Resolute Holdings Management RHLD Stock Holding History

PharVision Advisers’s Portfolio RHLD Stock Details RHLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,845
Closed -$205K – 1058
2025
Q3 		$205K Buy
+2,845
New +$154K 0.12% 497

Other funds holding RHLD

LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCP
Balance Capital Partners New York $87.9M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's RHLD Position: Q4 2025 in Review

PharVision Advisers sold out of Resolute Holdings Management (RHLD) in Q4 2025, closing a stake of 2,845 shares — an estimated $205K sold.

PharVision Advisers first reported a position in RHLD in Q3 2025 and held it in 1 quarter. The position peaked at $205K in Q3 2025. 122 funds tracked by Wall St. Rank hold RHLD as of Q4 2025.

  • PharVision Advisers reported no remaining Resolute Holdings Management position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 2,845 Resolute Holdings Management shares in Q4 2025, an estimated $205K.
  • PharVision Advisers first reported a position in Resolute Holdings Management in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Resolute Holdings Management position peaked at $205K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Resolute Holdings Management as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.